Achieve Life Sciences (ACHV) completed the US Food and Drug Administration long-term exposure requirement for cytisinicline, a treatment designed to help people quit smoking, with no safety concerns identified.
More than 300 participants completed six months of cumulative cytisinicline treatment in the ORCA-OL clinical trial, the company said Tuesday in a statement.
The company remains on track for the planned New Drug Application submission in Q2.
The company's shares rose 6.2% in recent Tuesday trading.
Price: 3.77, Change: +0.22, Percent Change: +6.20
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.